Bernard Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bernard Chan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Amanda Varghese
Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia
2 shared publications- Brendon Lange Neuen
The George Institute for Global Health, University of New South Wales, Sydney, Australia
2 shared publications Clare Arnott
Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
2 shared publicationsEmma O’lone
Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
2 shared publications- Geoffrey H. Tofler
Department of Cardiology Royal North Shore Hospital St Leonards New South Wales Australia
2 shared publications Glenn M. Chertow
Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
2 shared publications
Latest Publications
- Open Access
- 29 January 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (4) , 1037-1049
Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD
- 29 January 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (4) , 1037-1049
Open AccessSystematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD
- Open Access
Effects of iron on cardiovascular, kidney and safety outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
Background and aims: Heart failure and chronic kidney disease (CKD) are closely linked, with iron deficiency being highly prevalent in both conditions. Yet, major cardiovascular and nephrology guidelines offer contrasting recommendations on the use of iron. We evaluated the effects of iron versus usual care/placebo on clinical outcomes in patients with CKD. Methods: We conducted a systematic review and meta-analysis of randomised trials of intravenous or oral iron in CKD (PROSPERO CRD42023453468). We searched Medline, Embase and the Cochrane Register from database inception until February 1, 2024 to identify eligible trials. We determined results overall and stratified by dialysis- and non-dialysis-requiring CKD using random effects models, with certainty of evidence assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The primary composite endpoint was heart failure hospitalisation or cardiovascular death. Results: We identified 45 trials that met our inclusion criteria. Compared to usual care/placebo, iron reduced the risk of the primary composite endpoint (1659 events; RR 0.84, 95% CI 0.75-0.94; moderate certainty) an effect consistent across dialysis and non-dialysis requiring CKD (P-heterogeneity=0.70). The effect on the primary endpoint appeared driven by both components of hospitalisation for heart failure (RR 0.77; 95% CI 0.61-0.96; moderate certainty) and cardiovascular death (RR 0.81; 95% CI 0.65-1.02; low certainty). The incidence of serious adverse events was lower for iron compared to usual care/placebo (RR 0.90, 95% CI 0.82-0.98; moderate certainty; P-heterogeneity=0.09). Conclusion: Iron therapies may reduce the risk of heart failure or cardiovascular death in patients with CKD. Randomised rials evaluating effects of iron on clinical outcomes are needed, especially in non-dialysis CKD, with or without anaemia.
Open AccessEffects of iron on cardiovascular, kidney and safety outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
Background and aims: Heart failure and chronic kidney disease (CKD) are closely linked, with iron deficiency being highly prevalent in both conditions. Yet, major cardiovascular and nephrology guidelines offer contrasting recommendations on the use of iron. We evaluated the effects of iron versus usual care/placebo on clinical outcomes in patients with CKD. Methods: We conducted a systematic review and meta-analysis of randomised trials of intravenous or oral iron in CKD (PROSPERO CRD42023453468). We searched Medline, Embase and the Cochrane Register from database inception until February 1, 2024 to identify eligible trials. We determined results overall and stratified by dialysis- and non-dialysis-requiring CKD using random effects models, with certainty of evidence assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The primary composite endpoint was heart failure hospitalisation or cardiovascular death. Results: We identified 45 trials that met our inclusion criteria. Compared to usual care/placebo, iron reduced the risk of the primary composite endpoint (1659 events; RR 0.84, 95% CI 0.75-0.94; moderate certainty) an effect consistent across dialysis and non-dialysis requiring CKD (P-heterogeneity=0.70). The effect on the primary endpoint appeared driven by both components of hospitalisation for heart failure (RR 0.77; 95% CI 0.61-0.96; moderate certainty) and cardiovascular death (RR 0.81; 95% CI 0.65-1.02; low certainty). The incidence of serious adverse events was lower for iron compared to usual care/placebo (RR 0.90, 95% CI 0.82-0.98; moderate certainty; P-heterogeneity=0.09). Conclusion: Iron therapies may reduce the risk of heart failure or cardiovascular death in patients with CKD. Randomised rials evaluating effects of iron on clinical outcomes are needed, especially in non-dialysis CKD, with or without anaemia.
- Open Access
- 28 July 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 203, 285-287
Emotional Stress and Physical Exertion as Triggers of Acute Myocardial Infarction
- 28 July 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 203, 285-287
Open AccessEmotional Stress and Physical Exertion as Triggers of Acute Myocardial Infarction
- Open Access
- 28 June 2023
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 3 (4) , oead068
Circadian variation in acute myocardial infarction and modification by coronary artery disease: a prospective observational study
A circadian variation in the onset of acute myocardial infarction (AMI) has been consistently described, characterized by a morning peak between 6 a.m. and noon.1 However, the mechanism and modifiers of the morning peak in AMI have not been fully elucidated. Since the coronary arteries vary in their susceptibility to sympathetic activity and to changes in systolic blood pressure which also display circadian variation, there may be a relationship between the culprit coronary artery and morning AMI. Since infarct location affects the incidence of acute heart failure and cardiovascular mortality post-MI,2 it is important to clarify whether coronary anatomy also modifies the circadian variation of AMI.
- 28 June 2023
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 3 (4) , oead068
Open AccessCircadian variation in acute myocardial infarction and modification by coronary artery disease: a prospective observational study
A circadian variation in the onset of acute myocardial infarction (AMI) has been consistently described, characterized by a morning peak between 6 a.m. and noon.1 However, the mechanism and modifiers of the morning peak in AMI have not been fully elucidated. Since the coronary arteries vary in their susceptibility to sympathetic activity and to changes in systolic blood pressure which also display circadian variation, there may be a relationship between the culprit coronary artery and morning AMI. Since infarct location affects the incidence of acute heart failure and cardiovascular mortality post-MI,2 it is important to clarify whether coronary anatomy also modifies the circadian variation of AMI.
- 1 October 2016
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 25 (10) , 2423-2429
Intravenous Thrombolysis for Acute Ischemic Stroke due to Cervical Internal Carotid Artery Occlusion
- 1 October 2016
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 25 (10) , 2423-2429
Intravenous Thrombolysis for Acute Ischemic Stroke due to Cervical Internal Carotid Artery Occlusion